Crystal Amber Fund (LSE:CRS), the Guernsey-based Investment company traded on AIM, has spent 2026 tightening its focus on a single dominant holding, Morphic Medical Inc (MMI). In August 2026 the fund announced a further US$8.2 million investment in the medical device business, taking its stake to approximately 97.9% of MMI's issued share capital, and it has since continued to publish monthly net asset value updates, most recently on 20 October 2026, and appointed a new non-executive director on 1 October 2026.
What the company does
Crystal Amber describes its approach as investing in a limited number of special situations where value can be realised regardless of market direction. Since March 2022 its stated priority has been to maximise the return of capital to shareholders, and according to its interim report it has returned more than £118 million since 2013. Its portfolio has historically included UK smaller companies such as De La Rue, which it exited in July 2025 after Atlas Holdings' Takeover bid.
Latest developments
The fund's governance has changed significantly this year. Its half-year report, published on 31 March 2026, set out proposals to replace Crystal Amber Asset Management (Guernsey) as investment manager with Global Fund Management Services, with Tarncourt Asset Management as investment adviser, following the departure of long-standing principal adviser Richard Bernstein. Shareholders voted on the changes at an extraordinary general meeting on 22 April 2026. The fund subsequently appointed a new nominated adviser and broker in July 2026.
The August 2026 investment in MMI was intended to support the pivotal US clinical study of its Reset system. The fund said the money removed a significant potential delay by avoiding a required pause in patient recruitment, which it said was accelerating. Reset already has European and UK regulatory approval, NUB reimbursement status in Germany and several international distribution agreements. US Food and Drug Administration approval is anticipated in 2028 or 2029.
Financial and Dividend picture
In the six months to 31 December 2025, net asset value per share edged down 0.5% to 177.49p, while total net Assets fell to approximately £107.4 million from £116.2 million at the end of June 2025. The chairman attributed the decline mainly to a £6.6 million share buyback and around £1.0 million of adverse currency movements. The fund bought back 4,648,847 shares at an average 19.45% discount to NAV, leaving 60,503,500 shares in issue excluding treasury. No dividend was declared for that period.
At 31 December 2025, MMI was valued at about £83.6 million, dwarfing the other holdings: Sigma Broking at £4.95 million, Allied Minds at about £3.8 million and Sutton Harbour at about £0.6 million. Cash stood at roughly £17.5 million.
Sector and index context
Within the FTSE AIM All Share Index, Crystal Amber sits among a small group of fixed-capital investment vehicles rather than operating companies. Its value now depends overwhelmingly on a privately held US medical technology business, making it behave more like a concentrated venture investment than a diversified smaller-companies fund.
Key risks
Concentration is the obvious risk: with MMI representing the large majority of net assets, any setback in the US trial, regulatory process or funding would weigh heavily on NAV. The chairman acknowledged in March 2026 that maximising value in MMI would take longer than previously envisaged. Valuing an unlisted holding also involves judgement, and continued investment in MMI competes with the stated aim of returning capital.
What to watch next
Shareholders will watch monthly NAV announcements, progress on MMI's US study enrolment, any outcome of Sigma Broking's sale discussions and the next annual results. The approach of the new management team to Buybacks and future capital returns will also be closely followed.
_11_17_2026_13_03_03_397921.jpg)
_11_17_2026_13_00_45_999777.jpg)




Please wait processing your request...